7Baggers
 Published on: 2025-09-29 18:08:01  newser.com Mon, 29 Sep 2025 23:08:01 GMT
 Arbutus: IP Drama With High Stakes (NASDAQ:ABUS)  Seeking Alpha Mon, 15 Sep 2025 07:00:00 GMT
 arbutus biopharma (nasdaq:abus) trading down 4.6% - here's why  MarketBeat Sun, 14 Sep 2025 15:50:49 GMT
 arbutus biopharma (nasdaq:abus) trading up 6.4% - still a buy?  MarketBeat Sat, 13 Sep 2025 17:33:45 GMT
 arbutus biopharma (nasdaq:abus) trading 6.4% higher - still a buy?  MarketBeat Sat, 13 Sep 2025 17:33:45 GMT
 Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit  TipRanks Wed, 10 Sep 2025 07:00:00 GMT
 arbutus biopharma’s patent ruling in pfizer lawsuit  TipRanks Tue, 09 Sep 2025 07:00:00 GMT
 nuveen llc takes position in arbutus biopharma corporation $abus  MarketBeat Sat, 06 Sep 2025 07:00:00 GMT
 published on: 2025-09-03 05:15:59  Newser Wed, 03 Sep 2025 10:15:59 GMT
 chart based analysis of arbutus biopharma corporation trends  Newser Sun, 31 Aug 2025 19:33:08 GMT
 published on: 2025-08-30 22:10:35  Newser Sun, 31 Aug 2025 03:10:35 GMT
 published on: 2025-08-29 01:29:55  Newser Fri, 29 Aug 2025 06:29:55 GMT
 published on: 2025-08-27 18:23:29  Newser Wed, 27 Aug 2025 23:23:29 GMT
 published on: 2025-08-27 13:25:30  Newser Wed, 27 Aug 2025 18:25:30 GMT

Arbutus Biopharma Corporation
(NASDAQ:ABUS) 

ABUS stock logo

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-del...

Founded: 2007
Full Time Employees: 78
CEO: William Bill Collier  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends